Cargando…

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection

BACKGROUND: Due to the limitations of existing treatment options for Clostridium difficile infection (CDI), new therapies are needed. OBJECTIVE: To review the available data on fidaxomicin regarding chemistry, mechanisms of action and resistance, in vitro activity, pharmacokinetic and pharmacodynami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhanel, George G, Walkty, Andrew J, Karlowsky, James A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pulsus Group Inc 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692299/ https://www.ncbi.nlm.nih.gov/pubmed/26744587

Ejemplares similares

Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015)

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
por: Lee, Christine, et al.
Publicado: (2016)

Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012)

Fidaxomicin for the Treatment of Clostridium Difficile Infection in the Pediatric Population - Not Quite So Soon Yet
por: Daniels, Tanya, et al.
Publicado: (2011)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland
por: van Engen, Anke, et al.
Publicado: (2015)

Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis
por: Zhanel, George G., et al.
Publicado: (2016)

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
por: Nathwani, Dilip, et al.
Publicado: (2014)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

A multi-center study of fidaxomicin use for Clostridium difficile infection
por: Shah, Dhara N., et al.
Publicado: (2016)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
por: Figueroa, Iris, et al.
Publicado: (2012)

Fidaxomicin Use and Clinical Outcomes for Clostridium difficile–Associated Diarrhea
por: Eiland, Edward H., et al.
Publicado: (2015)

Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies
por: Soriano, Melinda M., et al.
Publicado: (2014)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

467 Analysis of Clinical and Economical Outcomes of Fidaxomicin Use for Clostridium difficile infections
por: Flaherty, Sarah, et al.
Publicado: (2014)

Fidaxomicin Use for Clostridium Difficile Infection Probably Decreases the Effect of Coumadin® in Elderly
por: Dhruv, Samyak, et al.
Publicado: (2020)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses
por: Cornely, Oliver A., et al.
Publicado: (2019)

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
por: Crook, Derrick W., et al.
Publicado: (2012)

500. Efficacy of 30-Day Fidaxomicin for Treatment of Acute Clostridium difficile Infection With History of Multiple Recurrences
por: Lee, Christine, et al.
Publicado: (2018)

Fidaxomicin for Clostridium difficile-Associated Diarrhoea: Epidemiological Method for Estimation of Warranted Price
por: Sclar, David Alexander, et al.
Publicado: (2012)

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections
por: Zhanel, George G., et al.
Publicado: (2020)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022)

Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada
por: Zhanel, George G., et al.
Publicado: (2018)

Whole-Genome Sequencing Demonstrates That Fidaxomicin Is Superior to Vancomycin for Preventing Reinfection and Relapse of Infection With Clostridium difficile
por: Eyre, David W., et al.
Publicado: (2014)

Impact of the use of local fidaxomicin treatment algorithms for managing Clostridium difficile infection in hospitalized patients in southeastern United States
por: Cho, Jonathan C., et al.
Publicado: (2018)

Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review
por: Al Momani, Laith A, et al.
Publicado: (2018)

Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections
por: Mullane, Kathleen M., et al.
Publicado: (2011)

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
por: Sattar, Abdul, et al.
Publicado: (2015)

Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin
por: Kuehne, Sarah A, et al.
Publicado: (2018)

A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin
por: Thabit, Abrar K., et al.
Publicado: (2016)

Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection
por: Sears, Pamela, et al.
Publicado: (2012)

1653 Results of a Treatment Protocol Encouraging First-Line Use of Fidaxomicin for Select Patients with Clostridium difficile Infection (CDI)
por: Navalkele, Bhagyashri, et al.
Publicado: (2014)

1987. Impact of Updated IDSA Clostridium difficile Guidelines on the use of Fidaxomicin in a Large Health System
por: Bariola, J Ryan, et al.
Publicado: (2019)

708. In Vitro Activity of Plazomicin vs. Clinical Isolates of Gram-Negative Bacilli, Including Aminoglycoside Nonsusceptible and Multidrug-Resistant Subsets, Recovered from Patients Across Canada as Part of the CANWARD study, 2011–2018
por: Walkty, Andrew, et al.
Publicado: (2019)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

Empyema caused by Clostridium bifermentans: A case report
por: Edagiz, Safa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6tp6tieqrbha8nrrupi0roq49b